TTI was recently mentioned in this article in the Cedar Rapids Gazette
By Dave DeWitte
…Several presenters were established businesses that are looking for funding, resources or ideas to let them grow.
Terpenoid Therapeutics’ Raymond Hohl seemed to dazzle his critique panel at the Seed and Venture Forum with his description of the company’s progress developing first-in-class small-molecule drugs to treat prostate cancer and brain cancer. The company aims to build value for investors by providing safety in human trials and then identifying a drug company partner to carry out further clinical development and take the products to market.
“It’s remarkable the amount of development you have been able to do on so little capital,” was one comment…